FDA advisory panel backs new opioid addiction drug

Shares of UK-listed Indivior (LSE: INDV) gained 11.28% to 413.50 pence in early trading this morning, following a positive outcome of a US Food Administration advisory panel vote on the firm's investigational drug RBP-6000.

Indivior, which was spun out of Reckitt Benckiser in 2014 and operates out of Virginia, USA, announced today that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA voted 18 to 1 to recommend approval of RBP-6000 for the treatment of opioid use disorder (OUD).

“I think this is a really promising alternative to what’s out there and will be attractive to a lot of patients,” said Laurel Habel, one of the panelists and researcher at Kaiser Permanente in Oakland, California.